Drug intelligence / Profile preview

inulin + oligofructose + bifidobacterium longum

Development stage
Unknown
Lead developer
Beneo-Orafti
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral
01

Overview

This combination is a synbiotic preparation consisting of the probiotic bacterium *Bifidobacterium longum* and the prebiotic fibers inulin and oligofructose. *Bifidobacterium longum* is a Gram-positive, rod-shaped, non-spore-forming bacterium that is a natural inhabitant of the human gastrointestinal tract. It provides health benefits by producing lactic acid, inhibiting the growth of pathogenic bacteria, and modulating the host's immune response. Inulin and oligofructose are non-digestible fructan-type carbohydrates that serve as selective substrates (prebiotics) to stimulate the growth and metabolic activity of beneficial bacteria like *Bifidobacteria* in the colon. The combination of these prebiotics with the probiotic strain aims to enhance the survival, colonization, and efficacy of *B. longum* in the gut, thereby improving intestinal microbiota balance, supporting the intestinal barrier, and potentially alleviating symptoms of gastrointestinal disorders such as irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD).

Brand names
Bifidophyl
Other names
Bifidobacterium longum with inulin and oligofructoseBifidobacterium longum with Synergy1

Beyond the preview

Go deeper on inulin + oligofructose + bifidobacterium longum.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on inulin + oligofructose + bifidobacterium longum.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call